Bringing Translational Insight to DLBCL Bispecific Development: TwinEdge to work with Hanx Biotherapeutics

As part of the collaboration, TwinEdge will develop individual digital twins (“avatars”) of a collection of Diffuse large B-cell lymphoma (DLBCL) Patient Derived Xenograft (PDX) mouse models (provided by Crown Bioscience, Inc.), integrating molecular and dose-response data into mechanistic simulations. The multi-phase goal of the collaboration is to further elucidate HX009’s mechanism of action, model potential clinical performance across lymphoma patients, and explore MoA relevance beyond the initial DLBCL focus.

Traditional preclinical readouts often limit how deeply early efficacy and variability can be understood. By computationally testing across thousands of simulated patients, the programme will explore heterogeneity across lymphoma patient populations and biomarker-linked response patterns. These insights aim to refine patient-selection hypotheses, strengthen early translational evidence for HX009, and help optimise clinical path planning.

Quotes :

Mike Prosser, CEO of TwinEdge Bioscience: “Hanx Biotherapeutics is progressing an exciting bispecific programme in a challenging oncology space. By combining their robust preclinical data with our digital avatar engine, we aim to extract richer insights not just into HX009’s efficacy, but the mechanisms and patient contexts in which it is most likely to succeed.”

Dr. Henry Li, CEO/CSO of Hanx Biotherapeutics: “HX009 has shown a compelling biological profile in the Crown PDX studies, and this partnership with TwinEdge gives us the ability to interrogate those results at a deeper level. TwinEdge’s digital avatar approach allows us to ask translational questions earlier — who responds, why, and what biomarkers matter most.”

Both companies look forward to sharing updates as the collaboration progresses.